[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370318-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370318-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeting-tubg1-in-rb1-negative-tumors","Targeting TUBG1 in RB1-negative tumors","","Microtubule dynamics disruption is an established cancer-killing strategy, yet its toxic effects on non-tumor cells limit therapeutic benefit. This study evaluates selective targeting of γ-tubulin1 (TUBG1) by defining the TUBG1–E2F1–retinoblastoma protein (RB1) network. A new compound, L12, increases RB1 expression and preferentially acts in cells with impaired RB1 signaling. Reduced E2F1 lowers L12 cytotoxicity, while L12-driven killing relies on E2F1-mediated procaspase 3 upregulation. Compared with traditional tubulin agents, L12 inhibits TUBG1 without affecting TUBG2 and achieves antitumor concentrations far below kinase-influencing levels.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-tubg1-in-rb1-negative-tumors/370318/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-tubg1-in-rb1-negative-tumors/370318.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What therapeutic strategy does the study focus on for cancer treatment?","Question",{"text":63,"@type":64},"The study investigates selectively targeting γ-tubulin1 (TUBG1) to eliminate tumor cells while aiming to reduce toxic effects seen with broader microtubule-targeting approaches.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the compound L12 affect the RB1 pathway?",{"text":68,"@type":64},"L12 treatment enhances RB1 expression and selectively targets cells with impaired RB1 signaling. Lowering E2F1 diminishes L12 cytotoxicity, linking the response to the E2F1–RB1 network.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanism underlies L12-induced cytotoxicity?",{"text":72,"@type":64},"L12-mediated cell killing depends on an E2F1-mediated upregulation of procaspase 3, supporting an apoptotic mechanism driven by E2F1 activity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370318,1790910094,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","DOI: 10.1096/fj.202403180RR  \nRESEAR CH ARTICLE  \nTargeting TUBG1 in RB1-negative tumors  \nLisa Lindström1  | Jingkai Zhou1  | Bruno O. Villoutreix2  | Darina Malycheva1 |  \nMagdalena Otrocka3  | Anna-Lena Gustavsson3  | Thomas Lundbäck3  | David Bliman4  | Muhammad Anwar Shameem4  | Megan Straw5 | Kristian Riesbeck5  | Roger Olsson4,6  | Maria Alvarado-Kristensson1   \n1Molecular Pathology, Department of Translational Medicine, Lund University, Malmö, Sweden 2Université Paris Cité, Inserm, NeuroDiderot, Paris, France  \n3Chemical Biology Consortium Sweden, Science for Life Laboratory, Karolinska Institutet, Solna, Sweden 4Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden 5Clinical Microbiology, Department of Translational Medicine, Lund University, Malmö, Sweden  \n6Chemical Biology & Therapeutics, Department of Experimental Medical Science, Lund University, Lund, Sweden  \nCorrespondence  \nMaria Alvarado-Kristensson, Molecular Pathology, Lund University, 53 Inga Marie Nilssons Street, Floor 2, Malmö SE-214 28, Sweden.  \nEmail: maria.alvarado-kristensson@ [med.lu.se](med.lu.se)  \nFunding information  \nCancerfonden (Swedish Cancer Society), Grant/Award Number: 22 2176Pj; Barncancerfonden (Swedish Childhood Cancer Foundation), Grant/ Award Number: PR2022-0058; BioCare, Grant/Award Number: 2012; Novo Nordisk foundation, Grant/Award Number: 12759; Skane University Hospital in Malmö Cancer Research, Grant/Award Number: 2022; Sten KJohnsons stiftelse (Sten K Johnson Foundation), Grant/Award Number:  \n2022; MultiPark (the Lund University Strategic Research Areas), Grant/Award Number: N/A; Swedish Research Council, Grant/Award Number:  \n2021-00179; SciLifeLab, Grant/Award Number: N/A  \nAbstract  \nThe disruption of microtubule dynamics serves as a pivotal strategy for eliminating tumor cells, despite its accompanying toxicities affecting non-tumor cells. This study investigates the potential of selectively targeting γ-tubulin1 (TUBG1) as a therapeutic strategy in cancer treatment. By elucidating the TUBG1– E2F1–retinoblastoma protein (RB1) network, we introduce a novel compound, 4-(6-((3-Methoxyphenyl)amino)pyrimidin-4-yl)-N,N-dimethylbenzenamine,(L12). L12 treatment enhanced RB1 expression and selectively targeted cells with impaired RB1 signaling, while reduced E2F1 expression attenuated its cytotoxicity. Furthermore, L12-mediated cytotoxicity depends on an E2F1-mediated upregulation of procaspase 3 expression, highlighting the role of E2F1 in the apoptotic response. Unlike traditional tubulin-targeting agents, L12's specificity for tumor cells lies in its inhibitory effects on TUBG1, without affecting the second human isoform of TUBGs, TUBG2 . Despite its interaction with specific kinases, the concentrations required for antitumor effects are 100-fold lower than those influencing kinase activities. Subsequent investigations underscore L12's reduced neuronal axonal toxicity compared to vincristine. Lastly, L12 demonstrates promising results in inhibiting tumor growth in xenografted small cell lung cancer models, demonstrating potential specificity toward tumor cells while minimizing adverse effects on healthy tissues. This research emphasizes the potential of  \n\n| Lisa Lindström and Jingkai Zhou contributed equally to this work. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.\u003Cbr>© 2025 The Author(s) . The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology. |\n\nThe FASEB Journal. 2025;39:e70431 .  \n[https://doi.org/10.1096/fj.202403180RR](https://doi.org/10.1096/fj.202403180RR)  \n[wileyonlinelibrary.com/journal/fsb2](wileyonlinelibrary.com/journal/fsb2 | 1 of 22)[ |](wileyonlinelibrary.c","cbCail7L4xPsU0DE","https://ap.wps.com/l/cbCail7L4xPsU0DE","pdf",8515780,22,"English","# Abstract\n# Introduction\n## Microtubule dynamics as an anticancer strategy\n## Tubulin family and the role of TUBG1/TUBG2\n## Discovery of the TUBG–E2F1–RB1 regulatory link","[{\"question\":\"What therapeutic strategy does the study focus on for cancer treatment?\",\"answer\":\"The study investigates selectively targeting γ-tubulin1 (TUBG1) to eliminate tumor cells while aiming to reduce toxic effects seen with broader microtubule-targeting approaches.\"},{\"question\":\"How does the compound L12 affect the RB1 pathway?\",\"answer\":\"L12 treatment enhances RB1 expression and selectively targets cells with impaired RB1 signaling. Lowering E2F1 diminishes L12 cytotoxicity, linking the response to the E2F1–RB1 network.\"},{\"question\":\"What mechanism underlies L12-induced cytotoxicity?\",\"answer\":\"L12-mediated cell killing depends on an E2F1-mediated upregulation of procaspase 3, supporting an apoptotic mechanism driven by E2F1 activity.\"}]","Targeting TUBG1 in RB1-negative tumors | PDF",1790187966,55,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/82edef0042531d27ffbb3d1a5cc58a8f.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dac1e9f989ce8741d55c2a3c102b01d7.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad4c908bfe086be3921a4d44dbee4520.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7bf6db00aea0ee466805ff029426ab30.webp",980,1287]